GSC Biological and Pharmaceutical Sciences
eISSN: 2581-3250 CODEN (USA): GBPSC2
Cross Ref DOI: 10.30574/gscbps
Journal homepage: https://gsconlinepress.com/journals/gscbps/

(REVIEW ARTICLE)

Check for updates

Pyrimidine derivatives: Their significance in the battle against malaria, cancer and viral infections

Sushma Somkuwar * and Neelesh Chaubey

Faculty of Pharmacy, Sri Satya Sai University of Technology and Medical Sciences, Sehore, M.P. India – 466001.

GSC Biological and Pharmaceutical Sciences, 2023, 25(02), 076–083

Publication history: Received on 20 September 2023; revised on 30 October 2023; accepted on 02 November 2023

Article DOI: https://doi.org/10.30574/gscbps.2023.25.2.0451

Abstract

Pyrimidine derivatives play a significant role in combating viral infections, malaria, and cancer due to their diverse pharmacological properties.

Pyrimidine derivatives, particularly nucleoside analogs, have been widely used as antiviral agents. They interfere with viral replication by inhibiting DNA or RNA synthesis.Examples include drugs like acyclovir (used against herpes viruses), lamivudine (for HIV and hepatitis B), and remdesivir (for COVID-19). These compounds help to manage and treat various viral infections, reducing their severity and spread. Pyrimidine derivatives are key components of antimalarial drugs like pyrimethamine and proguanil. They target the parasite Plasmodium falciparum's dihydrofolate reductase enzyme, essential for its survival. These drugs have been instrumental in combating malaria, a major global health concern, by inhibiting the growth of the malaria parasite within the human body. Pyrimidine analogs are used in chemotherapy to target rapidly dividing cancer cells. Drugs like 5-fluorouracil (5-FU) and cytarabine inhibit DNA synthesis in cancer cells, leading to cell death. These derivatives have been crucial in the treatment of various cancers, helping to slow down tumor growth and improve patient outcomes.

Overall, this article aims to consolidate existing knowledge on the topic, synthesize relevant information, and contribute to a better understanding of the potential applications of pyrimidine derivatives in the fields of oncology, virology, and tropical medicine.

Keywords: Pyrimidine Derivatives; Malaria; Cancer; Viral Infection; DNA; Combination Therapy

1. Introduction

Pyrimidine derivatives are a class of organic compounds that play a significant role in drug discovery and pharmaceutical research. Pyrimidines are a type of heterocyclic compound, composed of a six-membered ring containing four carbon atoms and two nitrogen atoms. Pyrimidine derivatives are essential building blocks in the synthesis of various biologically active molecules, including drugs. Here, the topic of pyrimidine derivatives and their significance in drug discovery has been introduced [1-2].

- **Structural Importance:** Pyrimidine derivatives are structurally important in biology and pharmacology because they are a fundamental component of many important biomolecules. For example, they are a part of the nucleic acids DNA and RNA, where they serve as the basis for genetic information storage and transfer [3].
- **Anticancer Agents:** Many pyrimidine derivatives have been developed into anticancer drugs. For instance, 5-fluorouracil (5-FU) is a widely used chemotherapeutic agent that inhibits DNA synthesis and is used in the

* Corresponding author: Sushma Somkuwar

treatment of various cancers, including colorectal cancer. Other pyrimidine-based drugs, such as cytarabine and gemcitabine, are also used in cancer therapy [4].

- **Antiviral Drugs:** Pyrimidine derivatives are used in the development of antiviral drugs. Zidovudine (AZT), a pyrimidine analog, was one of the first drugs approved for the treatment of HIV/AIDS. It acts by inhibiting reverse transcriptase, an enzyme necessary for the replication of the HIV virus [5].
- **Antibacterial Agents:** Some pyrimidine derivatives are employed as antibacterial agents. Trimethoprim, for example, is used to treat bacterial infections by inhibiting dihydrofolate reductase, an enzyme involved in the synthesis of DNA and RNA in bacteria [6].
- **Neurological Drugs:** Pyrimidine derivatives have applications in the field of neuroscience. Allopurinol, a pyrimidine analog, is used to treat conditions like gout and certain neurological disorders by inhibiting the production of uric acid [7].
- **Significance in Drug Design:** The structural versatility of pyrimidine derivatives makes them valuable in drug design and discovery. Medicinal chemists can modify the pyrimidine core by adding various functional groups to create new compounds with desired pharmacological properties, such as increased bioavailability, enhanced target specificity, or reduced side effects [8].
- **Targeting Enzymes:** Pyrimidine derivatives can be designed to specifically target enzymes involved in disease processes. By inhibiting or modulating these enzymes, researchers can develop drugs that interfere with the underlying mechanisms of various diseases, including cancer, viral infections, and metabolic disorders [9].

This article aims to provide a comprehensive overview of the existing literature related to pyrimidine derivatives and their potential activities against cancer, viral infections, and malaria. The review also aims to compare and contrast the effectiveness of pyrimidine derivatives in different contexts and to highlight any emerging trends or novel approaches in the development of pyrimidine derivatives for anticancer, antiviral, and antimalarial applications. This could include discussions on recent research findings and potential areas for future research.

2. Antiviral Activity of Pyrimidine Derivatives

Pyrimidine derivatives have been investigated for their potential use in treating various viral diseases, including HIV (Human Immunodeficiency Virus), hepatitis, and influenza. Pyrimidine derivatives have shown promise in inhibiting viral replication and are being explored as potential antiviral agents. Here's an overview of their role in combating these viral infections:

2.1. HIV (Human Immunodeficiency Virus)

HIV is a retrovirus that attacks the immune system, specifically CD4 T cells, leading to acquired immunodeficiency syndrome (AIDS). Pyrimidine derivatives, such as nucleoside analog reverse transcriptase inhibitors (NRTIs), have been a cornerstone of HIV treatment. These compounds mimic the structure of natural nucleosides and are incorporated into the viral DNA during reverse transcription, leading to premature termination of the viral DNA chain. Well-known NRTIs include zidovudine (AZT), lamivudine (3TC), and emtricitabine (FTC). These drugs help control viral replication and delay disease progression when used in combination with other antiretroviral drugs [10-11].

2.2. Hepatitis

Hepatitis viruses, particularly hepatitis B virus (HBV) and hepatitis C virus (HCV), can cause chronic liver infections that may lead to cirrhosis and liver cancer. Pyrimidine derivatives like lamivudine have been investigated for their role in treating chronic hepatitis B. Lamivudine inhibits the reverse transcriptase enzyme of HBV, reducing viral replication. For hepatitis C, pyrimidine analogs have been explored as potential inhibitors of the viral RNA-dependent RNA polymerase (NS5B). Sofosbuvir, a prodrug of a uridine analog, is a successful example of such an antiviral agent used in combination therapy to treat HCV [12-13].

2.3. Influenza

Influenza viruses cause seasonal outbreaks of the flu and can lead to severe respiratory infections. Pyrimidine derivatives have been studied as potential inhibitors of viral RNA polymerase in influenza viruses. Compounds like oseltamivir (Tamiflu) and zanamivir (Relenza) are neuraminidase inhibitors, which prevent the release of newly formed influenza virus particles from host cells. While not pyrimidine derivatives, these antiviral drugs target essential viral enzymes and are used to treat and prevent influenza infections [14].

Research on pyrimidine derivatives as antiviral agents has yielded several important studies and findings. Here are some key research studies and their findings in this field.

2.4. Lamivudine (3TC) for HIV/AIDS

Lamivudine is a pyrimidine derivative that has been extensively studied as an antiviral agent for HIV/AIDS. Research has shown that Lamivudine inhibits the reverse transcriptase enzyme of HIV, effectively slowing down viral replication. It is often used in combination therapy to enhance its antiviral efficacy and reduce the development of drug resistance [15].

2.5. Sofosbuvir for Hepatitis C

Sofosbuvir is a nucleotide analog, which is a type of pyrimidine derivative, used to treat hepatitis C virus (HCV) infections. Studies have demonstrated that Sofosbuvir inhibits the HCV RNA polymerase, leading to a significant reduction in viral load. It has revolutionized HCV treatment, offering high cure rates with minimal side effects [16].

2.6. Ribavirin for Respiratory Syncytial Virus (RSV)

Ribavirin is a pyrimidine derivative that has been studied for its antiviral properties against RSV, a common respiratory virus. Research has indicated that Ribavirin can inhibit RSV replication and reduce the severity of symptoms, particularly in severe cases and in immunocompromised individuals [17].

2.7. Remdesivir for Ebola and COVID-19

Remdesivir, a pyrimidine analog, was initially developed for Ebola virus and later repurposed for COVID-19. Studies have shown that Remdesivir can inhibit the RNA-dependent RNA polymerase of various viruses, including SARS-CoV-2. It received emergency use authorization for the treatment of COVID-19 and has been a key therapeutic option during the pandemic [18].

2.8. Tenofovir for Hepatitis B and HIV

Tenofovir is a pyrimidine derivative used to treat both hepatitis B virus (HBV) and HIV. Research has demonstrated its effectiveness in reducing viral replication and improving clinical outcomes in patients with these infections [19].

2.9. Brincidofovir for Adenovirus and Other DNA Viruses

Brincidofovir is a lipid-conjugated pyrimidine derivative developed for the treatment of various DNA viruses, including adenoviruses. Studies have shown promise in its ability to inhibit the replication of adenoviruses, especially in immunocompromised patients [20].

2.10. Pyrimidine-Based Broad-Spectrum Antivirals

Ongoing research aims to develop pyrimidine-based broad-spectrum antiviral agents that can target multiple viruses. These compounds are designed to interfere with conserved viral replication processes, offering potential treatments for emerging viral threats.

3. Antimalarial Activity of Pyrimidine Derivatives

Pyrimidine derivatives have been extensively studied for their antimalarial activity. Malaria is a deadly infectious disease caused by the Plasmodium parasite, which is transmitted to humans through the bite of infected female Anopheles mosquitoes. Antimalarial drugs are essential for the prevention and treatment of malaria. Pyrimidine derivatives have shown promise as potential antimalarial agents due to their ability to target specific aspects of the parasite's life cycle [21]. Here are some key points related to the antimalarial activity of pyrimidine derivatives:

- **Mechanism of Action:** Pyrimidine derivatives can target various stages of the Plasmodium parasite's life cycle, including inhibition of DNA synthesis and disruption of key metabolic pathways. They can interfere with the parasite's ability to replicate and survive within the human host [22].
- **Antifolate Drugs:** One well-known class of antimalarial drugs based on pyrimidine derivatives is the antifolate drugs, such as pyrimethamine and proguanil. These drugs inhibit the parasite's ability to synthesize folate, a crucial cofactor for DNA synthesis. By blocking folate synthesis, these drugs disrupt the replication of the parasite's genetic material, ultimately leading to its death [23].
- **Combination Therapy:** Due to the emergence of drug-resistant strains of Plasmodium, combination therapy is often employed in malaria treatment. Pyrimidine derivatives are commonly used in combination with other

antimalarial drugs, such as sulfadoxine and dapsone (in the case of sulfadoxine-pyrimethamine), to enhance treatment efficacy and reduce the risk of resistance [24].

- **New Drug Development:** Ongoing research aims to develop novel pyrimidine-based compounds with improved antimalarial activity and reduced side effects. Medicinal chemists work to design and synthesize new derivatives to combat drug resistance and improve treatment outcomes [25].
- **Mode of Administration:** Pyrimidine-derived antimalarials are typically administered orally, making them suitable for both treatment and prevention (prophylaxis) of malaria.
- The efficacy of pyrimidine derivatives against Plasmodium species varies depending on the specific compound, its mechanism of action, and the Plasmodium species involved. Here are some examples of pyrimidine derivatives and their efficacy:
- **Atovaquone:** Atovaquone, a pyrimidine derivative, is used in combination with proguanil (Malarone) to treat and prevent malaria. It acts on the mitochondrial electron transport chain and is effective against both Plasmodium falciparum and Plasmodium vivax. However, resistance to atovaquone has been reported in some regions [26].
- **Sulfadoxine-pyrimethamine:** This combination drug, also known as Fansidar, inhibits folate metabolism in Plasmodium parasites. It was once a widely used antimalarial but has faced increasing resistance, particularly in P. falciparum [27].
- **Dihydroorotate dehydrogenase (DHODH) inhibitors:** Compounds targeting DHODH, such as DSM265, are in development and show promise against various Plasmodium species. They disrupt pyrimidine biosynthesis and have the potential to be effective against drug-resistant strains [28].
- **Trimethoprim-sulfamethoxazole:** This combination is effective against P. falciparum and P. vivax by interfering with folate metabolism. However, its use is limited due to the development of resistance [29].
- **Combination Therapies with Artemisinin:** Clinical trials have explored combinations of pyrimidine-based antimalarials, such as pyrimethamine, with artemisinin-based drugs to combat drug-resistant strains of malaria. These combinations have been effective in delaying the emergence of resistance [30].
- **Chemical Modifications and Drug Development:** Research has also focused on the development of new pyrimidine-based antimalarials with improved efficacy and reduced resistance potential. These efforts involve chemical modifications of existing drugs and the discovery of novel compounds.

4. Anticancer Activity of Pyrimidine Derivatives

Pyrimidine derivatives have been a subject of interest in medicinal chemistry and cancer research due to their potential anticancer activity. Pyrimidines are a class of heterocyclic compounds that are structural components of DNA and RNA, making them essential for cell growth and replication. Modifying pyrimidine derivatives can disrupt these processes, potentially leading to anticancer effects [31-32]. Here are some key aspects of the anticancer activity of pyrimidine derivatives:

- **Inhibition of DNA and RNA Synthesis:** Pyrimidine analogs can interfere with the synthesis of DNA and RNA, which are critical processes for cancer cell proliferation. By inhibiting these processes, pyrimidine derivatives can slow down or halt cancer cell growth [33].
- **Targeting Thymidylate Synthase:** Thymidylate synthase is an enzyme that plays a crucial role in DNA synthesis. Some pyrimidine analogs, such as 5-fluorouracil (5-FU), act as antimetabolites and inhibit thymidylate synthase. This disruption in DNA synthesis can lead to cell death, making these compounds useful in cancer chemotherapy [34].
- **Induction of Apoptosis:** Certain pyrimidine derivatives can induce apoptosis, a programmed cell death process. This is a desirable effect in cancer treatment because it can eliminate cancer cells without harming healthy cells [35].
- **Tyrosine Kinase Inhibition:** Tyrosine kinases are enzymes that play a role in cell signaling and cancer progression. Some pyrimidine derivatives, such as imatinib (Gleevec), are tyrosine kinase inhibitors that have been successful in treating specific types of cancer, such as chronic myeloid leukemia (CML) [36].
- **Combination Therapies:** Pyrimidine derivatives are often used in combination with other chemotherapy agents or targeted therapies to enhance their anticancer effects. Combinations can help overcome drug resistance and improve treatment outcomes [37].
- **Selective Targeting:** Researchers are continually working on developing pyrimidine derivatives that selectively target cancer cells while sparing normal cells. This selectivity is essential to reduce the side effects of chemotherapy [38].

- Pyrimidine derivatives have been explored as potential anticancer agents due to their ability to interfere with DNA synthesis and replication, which is a key process in cancer cell proliferation. Here are some examples of pyrimidine derivatives that have shown promise as anticancer agents:
- **5-Fluorouracil (5-FU):** 5-FU is a well-known pyrimidine analog that has been used in cancer therapy for many years. It is converted into active metabolites within cells and inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. This disruption in DNA synthesis leads to cell death, making 5-FU effective against various types of cancer, including colorectal cancer [39].
- **Cytarabine (Ara-C):** Cytarabine is another pyrimidine analog used in the treatment of various hematologic malignancies, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It inhibits DNA polymerase, leading to chain termination during DNA replication [40].
- **Gemcitabine:** Gemcitabine is a nucleoside analog that incorporates into DNA strands during replication, causing premature termination. It is used to treat several types of cancer, including pancreatic, lung, and bladder cancers [41].
- **Tegafur-Uracil (UFT):** UFT is an oral prodrug of 5-FU that is often used in combination with other agents for the treatment of colorectal and breast cancers [42].
- **Raltitrexed:** Raltitrexed is a thymidylate synthase inhibitor, similar to 5-FU, and is used in the treatment of colorectal cancer [43].
- **Fludarabine:** Although primarily used in the treatment of chronic lymphocytic leukemia (CLL) and indolent lymphomas, fludarabine is a purine analog that also affects pyrimidine metabolism, leading to DNA synthesis inhibition [44].

5. Challenges and Future Directions

The development of pyrimidine-based drugs, while promising, comes with several limitations and challenges that researchers and pharmaceutical companies must address. Pyrimidine-based compounds have been widely explored for their potential therapeutic applications, including cancer treatment and antiviral drugs. Here are some of the key limitations and challenges associated with the development of pyrimidine-based drugs:

- **Off-Target Effects:** One of the primary challenges in drug development is achieving specificity for the target molecule while minimizing off-target effects. Pyrimidine-based drugs may interact with unintended proteins or pathways, leading to adverse effects and reduced efficacy. Achieving high selectivity for the target is a significant challenge.
- **Resistance Development:** Resistance to pyrimidine-based drugs can develop over time, particularly in the case of antiviral drugs. Pathogens or cancer cells may mutate and develop mechanisms to evade the drug's effects, rendering it less effective or completely ineffective. This necessitates ongoing research to develop new drug candidates with improved resistance profiles.
- **Toxicity:** Pyrimidine-based compounds can exhibit toxicity, which limits their therapeutic potential. Researchers need to carefully evaluate the safety profiles of these drugs and minimize their toxic effects on healthy cells and tissues.
- **Metabolism and Pharmacokinetics:** The metabolism of pyrimidine-based drugs in the body can be complex, leading to issues related to drug absorption, distribution, metabolism, and excretion (ADME). Understanding and optimizing these pharmacokinetic properties are essential for drug efficacy.
- **Bioavailability:** Achieving adequate bioavailability, which is the proportion of the administered dose that reaches the systemic circulation, can be challenging for some pyrimidine-based compounds. Poor bioavailability can reduce the effectiveness of the drug and necessitate higher doses, increasing the risk of adverse effects.
- **Drug-Drug Interactions:** Pyrimidine-based drugs can interact with other medications, leading to unwanted drug-drug interactions. These interactions can affect drug efficacy and safety and may require careful management when used in combination therapies.
- **Development Costs and Time:** The process of developing a new drug, from discovery to approval, is expensive and time-consuming. Pyrimidine-based drug development is no exception, and researchers and pharmaceutical companies must allocate significant resources to navigate the regulatory hurdles and clinical trials required for approval.
- **Intellectual Property and Competitive Landscape:** The pharmaceutical industry is highly competitive, and the intellectual property landscape can be complex. Companies must navigate patent challenges and market competition, which can impact the commercial viability of pyrimidine-based drugs.

- **Patient Stratification:** Tailoring pyrimidine-based drug treatments to specific patient populations based on genetic or molecular markers can be challenging but is crucial for maximizing efficacy and minimizing adverse effects. Personalized medicine approaches are increasingly important in drug development.
- **Regulatory Hurdles:** Meeting regulatory requirements and obtaining approval from regulatory agencies such as the FDA or EMA can be a significant challenge. Safety and efficacy data must be rigorously demonstrated in clinical trials, and regulatory processes can be lengthy.

6. Conclusion

In summary, pyrimidine derivatives have made substantial contributions to the fields of antiviral, antimalarial, and anticancer research. Their versatility in disrupting nucleic acid metabolism and replication processes has led to the development of various drugs that have proven effective in combating viral infections, malaria, and cancer. To make further progress in harnessing pyrimidine derivatives as effective anticancer agents, it is imperative for researchers to explore novel compounds, study their mechanisms of action, and conduct extensive preclinical and clinical trials. By doing so, we can identify more targeted and less toxic treatments that can significantly improve the prognosis and quality of life for cancer patients. Continued research and development in this area hold the promise of saving countless lives, reducing suffering, and advancing our understanding of these devastating diseases.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Rani Jyoti, et al. Design, synthesis and biological potentials of novel tetrahydroimidazo[1,2-a] pyrimidine derivatives. Chem. Cent. J. 2017, 11:16.

[2] Sharanabasappa B Patil., Biological and medicinal significance of pyrimidines: A Review. IJPSR. 2018, 9(1):44–52

[3] Jeelan Basha N., et al. A comprehensive review on pyrimidine analogs-versatile scaffold with medicinal and biological potential. J. Mol. Struct. 2021, 1246(15)

[4] Qurat-ul-Ain, et al. Free radical scavenging and cytotoxic activities of substituted pyrimidines. Canc. Ther. Oncol. Int. J. 2020, 16(3)

[5] Huang B., et al. Design, synthesis, and biological evaluation of piperidinyl-substituted [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential anti-HIV-1 agents with reduced cytotoxicity. Chem. Biol. Drug Des. 2021, 97:67–76

[6] Lahsani Siham, et al. Synthesis, characterization, and antibacterial and anti-inflammatory activities of new pyrimidine and thiophene derivatives. J. Chem. 2018, 8536063:1–11.

[7] Sun Y., Zhou Y.-Q., Liu Y.-K., Zhang H.-Q., Hou G.-G., Meng Q.-G., Hou Y. Potential anti-neuroinflammatory NF-κB inhibitors based on 3,4-dihydronaphthalen-1(2H)-one derivatives. J. Enzyme Inhib. Med. Chem. 2020, 35:1631–1640.

[8] Dweedar H.E., Mahrous H., Ibrahim H.S., Abdel-Aziz H.A. Analogue-based design, synthesis and biological evaluation of 3-substituted-(methylenehydrazono)indolin-2-ones as anticancer agents. Eur. J. Med. Chem. 2014, 78:275–280.

[9] Byl J.A.W., Cline S.D., Utsugi T., Kobunai T., Yamada Y., Osheroff N. DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for drug action. Biochemistry. 2001, 40:712–718.

[10] Romeo Roberto, et al. Pyrimidine 2,4. Diones in the Design of New HIV RT Inhibitors. Molecules. 2019, 24(9):1718.

[11] Kang D., et al. Identification of dihydrofuro[3,4- d]pyrimidine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors with promising antiviral activities and desirable physicochemical properties. J. Med. Chem. 2019, 62(3):1484–1501.

[12] Simons, C., Wu, Q., Htar, T. Recent advances in antiviral nucleoside and nucleotide therapeutics. Curr. Top. Med. Chem. 2005, (5):1191– 1203

[13] Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 1996, 24:714–717.

[14] Hayden, F. G., Cote, K. M., Douglas, R. G. Plaque Inhibition Assay for Drug Susceptibility Testing of Influenza Viruses. Antimicrob. Agents Chemother. 1980, (17) 865– 870

[15] Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004, 351:1206–1217

[16] Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 on patients without treatment options. N Engl J Med. 2013, 368(20):1867–1877.

[17] Elgemeie, G. H., Abu-Zaied, M. A., Nawwar, G. A. First Novel Synthesis of Triazole Thioglycosides as Ribavirin Analogues. Nucleosides, Nucleotides Nucleic Acids 2018, (37) 112– 123

[18] Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., Götte, M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020, (295), 6785– 6797

[19] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016, 1(3):196–206.

[20] Chittick G., Morrison M., Brundage T., Nichols W.G. Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox. Antivir. Res. 2017, 143:269–277.

[21] Krettli, A.U., Adebayo, J.O., Krettli, L.G. Testing of natural products and synthetic molecules aiming at new antimalarials. Curr. Drug Targets 2009, (10) 261–270.

[22] Zhu, S., Zhang, Q., Gudise, C., Meng, L., Wei, L., Smitha, E., Kong, Y. Synthesis and evaluation of naphthyridine compounds as antimalarial agents. Bioorg. Med. Chem. Lett. 2007, 17, 6101–6106.

[23] Chittick G., Morrison M., Brundage T., Nichols W.G. Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox. Antivir. Res. 2017, 143:269–277.

[24] Phillips, M.A., Rathod, P.K. Plasmodium dihydroorotate dehydrogenase: A promising target for novel anti-malarial chemotherapy. Infect. Dis. Drug Targets 2010, (10) 226–239.

[25] Gujjar, R., El Mazouni, F., White, K.L., White, J., Creason, S., Shackleford, D.M., Deng, X., Charman, W.N., Bathurst, I., Burrows, J., et al. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J. Med. Chem. 2011, (54) 3935–3949

[26] Baggish AL, Hill DR. Antiparasitic agent atovaquone. Antimicrobial agents and chemotherapy 2002, 46(5):1163–73.

[27] De Kock M, Tarning J, Workman L, et al. Pharmacokinetics of sulfadoxine and pyrimethamine for intermittent preventive treatment of malaria during pregnancy and after delivery. CPT Pharmacometrics Syst Pharmacol 2017, 6: 430–438.

[28] Baumann P, Mandl-Weber S, Volkl A, et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther. 2009, 8:366–375.

[29] Howe RA, Spencer RC. Cotrimoxazole. Rationale for re-examining its indications for use. Drug Saf. 1996, 14:213–8.

[30] Xu C, Wong YK, Liao FL, Jiang T, Wang J, Tu Y. Is triple artemisinin-based combination therapy necessary for uncomplicated malaria? Lancet Infect Dis. 2022, 22:585–86.

[31] Elgemeie, G. H., Abu-Zaied, M. A., Loutfy, S. A. 4-Aminoantipyrine in carbohydrate research: Design, synthesis and anticancer activity of thioglycosides of a novel class of 4-aminoantipyrines and their corresponding pyrazolopyrimidine and pyrazolopyridine thioglycosides. Tetrahedron 2017, (73) 5853– 5861

[32] Kaled R.A.A., et al. Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment. Med. Chem. Res. 2021, 30:31–49.

[33] Tylinska Beata, et al. Novel pyrimidine derivatives as potential anticancer agents: synthesis, biological evaluation and molecular docking study. Int. J. Mol. Sci. 2021, 22(8):3825.

[34] Lombardo L.J., et al. Discovery of N-(2- Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004, 47(27):6658–6661.

[35] Xie F., Zhao H., Zhao L., Lou L., Hu Y. Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity. Bioorgan. Med. Chem. Lett. 2009, 19:275–278.

[36] Tylinska B., Jasztold-Howorko R., Kowalczewska K., Szczaurska-Nowak K., Gbarowski T., Wietrzyk J. Design, synthesis and analysis of anticancer activity of new SAR-based S16020 derivatives. Acta Pol. Pharm. Drug Res. 2018

[37] Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol. 2013, (31):1592–605.

[38] Chikamori K., Grozav A., Kozuki T., Grabowski D., Ganapathi R., K Ganapathi M. DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy. Curr. Cancer Drug Targets. 2010, 10:758–771.

[39] Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BY, Kopp MV, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei YJ, Galimi F, et al. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol. 2013(24):1777–85.

[40] DiPersio JF, Erba HP, Larson RA, Luger SM, Tallman MS, Brill JM, Vuagniaux G, Rouits E, Sorensen JM, Zanna C. Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. Clin Lymphoma Myeloma Leuk. 2015(15):443–9.

[41] Jones SF, Infante JR, Spigel DR, Peacock NW, Thompson DS, Greco FA, McCulloch W, Burris HA. Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors. Cancer Invest. 2012(30):481–6.

[42] Lembersky B.C., Wieand H.S., Petrelli N.J., O'Connell M.J., Colangelo L.H., Smith R.E., et al. (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24: 2059–2064

[43] Kerr DJ. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer. Anticancer Drugs 1997, 8 Suppl 2:S11-5. 10.1097/00001813-199708002-00003

[44] Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007, 370:230–239.